Here are 1-2 brief analogies for Evoke Pharma:

• Vertex Pharmaceuticals for gastrointestinal disorders.

• Acadia Pharmaceuticals for gastrointestinal disorders.

• Gimoti: A metoclopramide nasal spray approved for the relief of acute and recurrent diabetic gastroparesis symptoms in adults.

Evoke Pharma (EVOK) sells primarily to other companies, specifically pharmaceutical wholesalers, who then distribute the product to pharmacies and ultimately to patients. The company has stated in its financial filings that a substantial portion, and often nearly all, of its net product sales are to a limited number of major pharmaceutical wholesalers in the United States.

The major customer companies for Evoke Pharma are:

• AmerisourceBergen Corporation (NYSE: ABC)
• Cardinal Health, Inc. (NYSE: CAH)
• McKesson Corporation (NYSE: MCK)

Catalent, Inc. (CTLT)

Recipharm AB (RECI)

Matthew J. D'Onofrio, Chief Executive Officer

Matthew J. D'Onofrio is a co-founder and Chief Executive Officer of Evoke Pharma, appointed CEO on March 31, 2024. He brings over 30 years of experience in the pharmaceutical industry, encompassing corporate leadership, business development, commercial strategy, and drug development. Since co-founding Evoke, he has been instrumental in leading key functions such as finance, operations, regulatory strategy, and commercialization, successfully overseeing the advancement and launch of GIMOTI. Before his time at Evoke, Mr. D'Onofrio held senior roles at Victory Pharma, Vertex Pharmaceuticals, and Eli Lilly & Company. At Vertex, his contributions supported the early funding and development of the company's cystic fibrosis program. While at Eli Lilly, he negotiated numerous strategic partnerships and licensing deals across various therapeutic areas.

Mark Kowieski, Chief Financial Officer

Mark Kowieski is the Chief Financial Officer of Evoke Pharma, a position he was appointed to in 2024. He possesses nearly 25 years of experience in corporate finance, accounting, and public company operations, with more than 15 years specifically within the life science industry. Mr. Kowieski joined Evoke in 2022 as Vice President of Finance and has since been pivotal in strengthening financial controls, scaling operations, and supporting commercial strategy. Prior to Evoke, he held leadership positions with increasing responsibilities at Evofem Biosciences and Vital Therapies, where he oversaw areas including SEC reporting, budgeting, and accounting operations. His career began at Arthur Andersen, and he has experience working in diverse industries across both public and private companies.

Marilyn R. Carlson, D.M.D., M.D., Chief Medical Officer

Marilyn R. Carlson serves as the Chief Medical Officer of Evoke Pharma. She has been a crucial clinical and regulatory expert for Evoke throughout the entire development process of GIMOTI (metoclopramide) nasal spray, including all supporting clinical trials. Dr. Carlson initially joined Evoke at its founding in 2007 as an outside consultant before becoming a full-time employee in December 2013.

Christopher Quesenberry, Chief Commercial Officer

Christopher Quesenberry is the Chief Commercial Officer for Evoke Pharma, specifically overseeing GIMOTI. He has over 30 years of experience in the pharmaceutical industry, focusing on building and executing commercial strategies. His career includes various roles in sales, marketing, and operations. Mr. Quesenberry spent 27 years with Merck & Co. and Novo Nordisk, holding senior sales and commercial strategy positions. He also served as the Vice President of Global Commercial Effectiveness at Orexigen Therapeutics and Nalpropion Pharmaceuticals.

Cam L. Garner, Chairman of the Board

Cam L. Garner is one of the co-founders of Evoke Pharma and has served as Chairman of its board of directors since June 2007. He has a notable history of co-founding multiple specialty pharmaceutical companies, including Zogenix, Inc., Cadence Pharmaceuticals, Inc., Somaxon Pharmaceuticals, Inc., Elevation Pharmaceuticals, Inc., DJ Pharma, Verus Pharmaceuticals, Inc., Xcel Pharmaceuticals, Inc., Meritage Pharma, Inc., Oncternal Therapeutics, Inc., Kalyra Pharmaceuticals, Inc., OrPro Therapeutics, Inc., Alastin Skincare, Inc., and Zavante Therapeutics, Inc. Mr. Garner has a pattern of managing companies that were subsequently acquired; he served as Chairman of Xcel Pharmaceuticals until its acquisition by Valeant Pharmaceuticals International, DJ Pharma until its sale to Biovail, Elevation Pharmaceuticals until its acquisition by Sunovion Pharmaceuticals Inc., Cadence Pharmaceuticals until its acquisition by Mallinckrodt plc, Meritage Pharma until its acquisition by Shire plc, Zavante Inc. until its acquisition by Nabriva, Alastin until its acquisition by Galderma, and Zogenix, Inc. until its acquisition by UCB. Additionally, he was the Chief Executive Officer of Dura Pharmaceuticals, Inc. from 1989 to 1995 and its Chairman and Chief Executive Officer from 1995 until it was sold to Elan in November 2000.

The key risks to Evoke Pharma (EVOK) primarily stem from its reliance on a single product, its ongoing financial challenges, and the significant safety warning associated with its main therapeutic offering.

1. Single Product Dependency: Evoke Pharma is "entirely dependent on the success of GIMOTI® (metoclopramide) nasal spray". This means that the company's entire business model and future prospects hinge on the continued market acceptance, efficacy, safety, and intellectual property protection of this one product. Any factor that negatively impacts GIMOTI, such as decreased demand, unexpected adverse side effects, challenges to its intellectual property, or the emergence of superior alternative treatments, could severely impact the company's operations and financial viability.
2. Financial Health and Need for Additional Financing: Evoke Pharma has a history of persistent unprofitability and cash burn, consistently reporting net losses. While the company has shown revenue growth, it continues to operate at a net loss, with an accumulated deficit of approximately $128.8 million as of December 31, 2024. The company anticipates needing substantial additional funding to support its operations and commercialization efforts for GIMOTI. Although analysts expect the company to approach breakeven around 2026, this projection relies on "optimistic" and "extremely buoyant" growth rates. Furthermore, Evoke Pharma carries a high debt-to-equity ratio, which can increase the risk associated with investing in a loss-making company.
3. Black Box Warning for Tardive Dyskinesia: GIMOTI carries an FDA black box warning for the risk of tardive dyskinesia (TD), a serious and potentially irreversible movement disorder. This severe warning legally limits the recommended duration of treatment to less than 12 weeks, significantly capping GIMOTI's potential for long-term chronic use and exposing the company to potential product liability claims. The presence of this warning can also affect prescribing patterns and overall market adoption.

One clear emerging threat to Evoke Pharma (EVOK) is the development of novel therapies for diabetic gastroparesis by competing pharmaceutical companies. Specifically, Reltecimod (a ghrelin receptor agonist) by Cinrx Pharma is currently in Phase 2 clinical trials for the treatment of gastroparesis. If successful in later-stage trials and approved, Reltecimod could represent a new treatment option with a different mechanism of action that directly competes with Evoke Pharma's Gimoti (metoclopramide) nasal spray in the diabetic gastroparesis market. Its progression through clinical development poses a direct, observable challenge to Evoke's market position.

Evoke Pharma (EVOK) anticipates several key drivers for future revenue growth over the next 2-3 years, primarily centered around its flagship product, Gimoti (metoclopramide) nasal spray, for diabetic gastroparesis:

1. Increased Prescriber Adoption: Evoke Pharma has demonstrated consistent growth in its prescriber base for Gimoti. The company reported a 20% year-over-year increase in new prescribers in Q2 2025 and a 44% growth in its total prescriber base in Q1 2025, reflecting expanding interest among healthcare providers. In Q3 2024, the cumulative prescriber base increased by 45% year-over-year.
2. Higher Prescription Fill Rates and Patient Adherence: The company has improved its prescription fill rates and observed sustained therapy adherence. In Q2 2025, refill rates remained steady at approximately 70%, and Q1 2025 saw a 73% year-over-year increase in fill rate. These improvements indicate effective commercial execution and continued patient benefit from Gimoti.
3. Expanded Pharmacy Access and Commercialization Efforts: Strategic initiatives to broaden pharmacy access and streamline distribution are contributing to revenue growth. The transition to ASPN Pharmacies in November 2023 has reportedly improved the conversion of prescriptions to fills and led to record-high prescription volumes. Evoke's partnership with Eversana also provides essential sales and marketing infrastructure.
4. Targeting the GLP-1 Receptor Agonist Patient Population: Evoke Pharma is strategically focusing on the growing diabetic population, particularly those undergoing GLP-1 therapy, for whom non-oral treatment options like Gimoti are highly relevant. Real-world data presented at ACG 2024 highlighted Gimoti's effectiveness in this patient segment. This focus addresses a specific market need and leverages the product's unique delivery method.

Share Issuance

• Evoke Pharma has experienced a significant increase in its outstanding shares, with a reported increase of 295.97% in one year.
• As of November 5, 2025, Evoke Pharma had 1,558,465 outstanding shares.
• Quarterly data indicates fluctuations, with 2.5 million shares outstanding on March 31, 2025, and 1.5 million on June 30, 2025.

Inbound Investments

• Evoke Pharma announced a definitive agreement to be acquired by QOL Medical, a privately held biopharmaceutical company, for $11.00 per share in cash.
• The total acquisition value for Evoke Pharma is approximately $18.9 million.
• This transaction, unanimously approved by both boards, is expected to close by the end of 2025.

Capital Expenditures

• Capital expenditures have been reported as nominal or very low in recent financial periods.
• For instance, capital expenditures were recorded as $5 for the quarter ending September 30, 2024.
• The company's primary operational spending focuses on Research & Development, and Selling, General & Administrative expenses, rather than significant capital asset acquisition.